Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Zymeworks Inc. before investing.

In this article, we go over a few key elements for understanding Zymeworks Inc.’s stock price such as:

• Zymeworks Inc.’s current stock price and volume
• Why Zymeworks Inc.’s stock price changed recently
• Upgrades and downgrades for ZYME from analysts
• ZYME’s stock price momentum as measured by its relative strength

About Zymeworks Inc. (ZYME)

Before we jump into Zymeworks Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Want to learn more about Zymeworks Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Zymeworks Inc..

Zymeworks Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Zymeworks Inc.’s stock price was $21.940.

Zymeworks Inc. is down 3.39% from its previous closing price of $22.710.

During the last market session, Zymeworks Inc.’s stock traded between $21.800 and $22.750. Currently, there are approximately 74.67 million shares outstanding for Zymeworks Inc..

Zymeworks Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Zymeworks Inc. Stock Price History

Zymeworks Inc.’s (ZYME) price is currently down 16.07% so far this month.

During the month of July, Zymeworks Inc.’s stock price has reached a high of $27.410 and a low of $21.800.

Over the last year, Zymeworks Inc. has hit prices as high as $29.750 and as low as $11.510. Year to date, Zymeworks Inc.’s stock is down 16.67%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Zymeworks Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Zymeworks Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Zymeworks Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Zymeworks Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Zymeworks Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Zymeworks Inc. (ZYME) by visiting AAII Stock Evaluator.

Relative Price Strength of Zymeworks Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Zymeworks Inc. has a weighted four-quarter relative price strength of 5.97%, which translates to a Momentum Score of 73 and is considered to be Strong.

Want to learn more about how Zymeworks Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Zymeworks Inc. Stock Price: Bottom Line

As of July 31, 2026, Zymeworks Inc.’s stock price is $21.940, which is down 3.39% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Zymeworks Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.